Increased PD-L1 expression and an immunologically active tumour microenvironment has been demonstrated for HPV-positive HNSCC, suggesting immunotherapy as a promising treatment option [44,45]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.